Physical exercise is increasingly recognized as a valuable treatment strategy in managing
prostate cancer, not only enhancing supportive care but potentially influencing disease outcomes. However, there are limited studies investigating mechanisms of the
tumor-suppressive effect of exercise. Recently, extracellular vesicles (EVs) have been recognized as a therapeutic target for
cancer as
tumor-derived EVs have the potential to promote metastatic capacity by transferring oncogenic
proteins,
integrins, and
microRNAs to other cells and EVs are also involved in developing drug resistance. Skeletal muscle has been identified as an endocrine organ, releasing EVs into the circulation, and levels of EV-containing factors have been shown to increase in response to exercise. Moreover, preclinical studies have demonstrated the
tumor-suppressive effect of
protein and
microRNA contents in skeletal muscle-derived EVs in various
cancers, including
prostate cancer. Here we review current knowledge of the
tumor-derived EVs in
prostate cancer progression and
metastasis, the role of exercise in skeletal muscle-derived EVs circulating levels and the alteration of their contents, and the potential
tumor-suppressive effect of skeletal muscle-derived EV contents in
prostate cancer. In addition, we review the proposed mechanism of exercise in the uptake of skeletal muscle-derived EVs in
prostate cancer.